Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes

Journal of Immunological Methods

Volumn 211, Issue 1-2, 1998, Pages 21-31

  Nardin, Alessandra ^a   Sutherland, William M ^a   Hevey, Michael ^b   Schmaljohn, Alan ^b   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b US Army Medical Research Institute of Infectious Diseases   (United States)

Author keywords

Erythrocyte complement receptor; Heteropolymers; Marburg virus

Indexed keywords

COMPLEMENT RECEPTOR;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; COMPLEMENT FIXATION; CONTROLLED STUDY; ERYTHROCYTE; MARBURG VIRUS; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; HUMANS; MARBURGVIRUS; MICE; MICE, INBRED BALB C; RADIOIMMUNOASSAY; RECEPTORS, COMPLEMENT 3B; VERO CELLS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; LAKE VICTORIA MARBURGVIRUS; PRIMATES;

EID: 0032004079     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(97)00168-3     Document Type: Article

References (37)

1. Brown, E.J., Hosea, S.W., Hammer, C.H., Burch, C.G., Frank, M.M., 1982. A quantitative analysis of the interaction of antipneumococcal antibody and complement in experimental bacteremia. J. Clin. Invest. 69, 85.
2. Chamow, S.M., Zhang, D.Z., Tan, X.Y., Mhatre, S.M., Marsters, S.A., Peers, D.H., Byrn, R.A., Ashkenazi, A., Junghans, R.P., 1994. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J. Immunol. 153, 4268.
3. Connor, R.I., Dinces, N.B., Howell, A.L., Romet-Lemonne, J.-L., Pasquali, J.-L., Fanger, M.W., 1991. Receptors for IgG (FcRs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): Studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including FcR. Proc. Natl. Acad. Sci. USA 88, 9593.
4. Cornacoff, J.B., Hebert, L.A., Smead, W.L., Van Aman, M.E., Birmingham, D.J., Waxman, F.J., 1991. Primate erythrocyte-immune complex-clearing mechanism. J. Clin. Invest. 71, 236.
5. Dimaggio, J.J., Scheinberg, D.A., Houghton, A.N., 1990. Monoclonal antibody therapy of cancer. Cancer Chemo. Biol. Res. Modifiers Annu. 2, 177.
6. Edberg, J.C., Tosic, L., Wright, E.L., Sutherland, W.M., Taylor, R.P., 1988. Quantitative analyses of the relationship between C3 consumption, C3b capture and immune adherence of complement-fixing antibody/DNA immune complexes. J. Immunol. 141, 4258.
7. Fanger, M.W., 1995. Introduction, vol. ix. In: Bispecific antibodies. Molecular Biology Intelligence Unit, R.G. Landes Company, Austin.
8. Fanger, M.W., Morganelli, P.M., Guyre, P.M., 1992. Bispecific antibodies. Crit. Rev. Immunol. 12, 101.
9. Fauci, A.S., 1996. Host factors and the pathogenesis of HIV-induced disease. Nature 384, 529.
10. Feldmann, H., Klenk, H.D., 1996. Marburg and Ebola viruses. Adv. Virus Res. 47, 1.
11. Ferguson, P.J., Reist, C.J., Martin, E.N., Johnson, C., Green, K.L., Kuhn, S., Niebur, J., Emlen, W., Taylor, R.P., 1995. Antigen-based heteropolymers: A potential therapy to bind and clear antoantibodies via erythrocyte CR1. Arthritis Rheum. 38, 190.
12. Fraker, P.J., Speck, J.C., 1978. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. Commun. 80, 849.
13. Grossbard, M.L., Press, O.W., Appelbaum, F.R., Bernstein, I.D., Nadler, L.M., 1992. Monoclonal antibodies based therapies of leukemia and lymphoma. Blood 80, 863.
14. Hebert, L.A., 1991. The clearance of immune complexes from the circulation of man and other primates. Am. J. Kidney Dis. 17, 352.
15. Hevey, M., Negley, D., Geisbart, J., Jahrling, P., Schmaljohn, A., 1997. Antigenicity and Vaccine Potential of Marburg Virus Glycoprotein expressed by Baculovirus Recombinants. Virol. 239, 206.
16. Ho, D.D., Moudgil, T., Alam, M., 1989. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321, 1621.
17. Kiley, M.P., Cox, N.J., Elliott, L.H., Sanchez, A., DeFries, R., Buchmeier, M.J., Richman, D.D., McCormick, J.B., 1988. Physicochemical properties of Marburg virus: Evidence for three distinct virus strains and their relationship to Ebola virus. J. Gen. Virol. 69, 1957.
18. Kuhn, S.E., Nardin, A., Taylor, R.P., 1997. Unpublished data.
19. Miller, L.H., Good, M.F., Milon, G., 1994. Malaria pathogenesis. Science 264, 1878.
20. Okada, H., Momota, H., Azuma, T., Hattori, T., Okada, N., 1992. Specific cytolysis of HIV-infected cells by lymphocytes armed with bifunctional antibodies. Immunol. Lett. 31, 247.
21. Pearlson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., Ho, D.D., 1996. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span and viral generation time. Science 271, 1582.
22. Reist, C.J., Combs, M.J., Croft, B.Y., Taylor, R.P., 1993. Antigens pre-bound to the primate erythrocyte complement receptor via cross-linked bispecific monoclonal antibody heteropolymers are rapidly cleared from the circulation. Eur. J. Immunol. 23, 3021.
23. Reist, C.J., Liang, H.Y., Denny, D., Martin, E.N., Scheld, W.M., Taylor, R.P., 1994. Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys. Eur. J. Immunol. 24, 2018.
24. Ross, G.D., Yount, W.J., Walport, M.J., Winfield, J.B., Parker, C.J., Taylor, R.P., Myones, B.L., Lachmann, P.J., 1985. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus, and other diseases involving autoantibodies and/or complement activation. J. Immunol. 135, 2005.
25. Schifferli, J.A., Taylor, R.P., 1989. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 35, 993.
26. Segal, D.M., Bast, B., 1995. Production of bispecific antibodies. Curr. Protocols Immunol. 2, 13.1.
27. Smith, T.J., 1995. Antibody recognition of viruses. Semin. Virol. 6, 217.
28. Spiegelberg, H.L., Miescher, P.A., Benacerraf, B., 1963. Studies on the role of complement in the immune clearance of Escherichia coli and rat erythrocytes by the reticuloendothelial system in mice. J. Immunol. 90, 751.
29. Taylor, R.P., Ferguson, P.J., 1995. Primate erythrocyte complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. J. Hematother. 4, 357.
30. Taylor, R.P., Sutherland, W.M., Reist, C.J., Webb, D.J., Wright, E.L., Labugen, R.H., 1991. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment. Proc. Natl. Acad. Sci. USA 88, 3305.
31. Taylor, R.P., Reist, C.J., Sutherland, W.M., Otto, A., Labuguen, R.H., Wright, E.L., 1992. In vivo binding and clearance of circulating antigen by bispecific heteropolymer-mediated binding to primate erythrocyte complement receptor. J. Immunol. 148, 2462.
32. Taylor, R.P., Sutherland, W.M., Martin, E.N., Ferguson, P.J., Reinagel, M.L., Gilbert, E., Lopez, K., Incardona, N.L., Ochs, H.D., 1997a. Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J. Immunol. 158, 842.
33. Taylor, R.P., Ferguson, P.J., Martin, E.N., Cooke, J., Greene, K.L., Grinspun, K., Guttman, M., Kuhn, S., 1997b. Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 Mabs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model. Clin. Immunol. Immunopathol. 82, 49.
34. Taylor, R.P., Martin, E.N., Reinagel, M., Nardin, A., Craig, M., Choice, Q., Shlimgen, R., Greenbaum, S., Incardona, N.L., Ochs, H.D., 1997c. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype pathogen in monkey model. J. Immunol. 159, 4035.
35. Titus, J.A., Perez, P., Kaubisch, A., Garrido, M.A., Segal, D.M., 1987. Human K/natural killer cells targeted with heterocross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J. Immunol. 139, 3153.
36. Wilchek, M., Bayer, E.A. (Eds.), 1990. Avidin-biotin technology. Methods Enzymol. 184.
37. Woods, G.L., Gutierrez, Y., 1993. Cardiovascular and hematopoietic systems. In: Diagnostic Pathology of Infectious Diseases. Lea and Febiger, Philadelphia, p. 573.